🇺🇸 FDA
Patent

US 10106796

Compound and method for treating myotonic dystrophy

granted A61PA61P21/00

Quick answer

US patent 10106796 (Compound and method for treating myotonic dystrophy) held by Sarepta Therapeutics, Inc. expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61P, A61P21/00